阿立派唑联合米氮平治疗躯体形式障碍患者的临床疗效及安全性研究  

Clinical efficacy and safety study of Aripiprazole combined with Mirtazapine in the treatment of patients with somatoform disorders

作　　者：蔡文婷 赖燕 廖梅蓉 赖忠红 肖峰 CAI Wen-ting;LAI Yan;LIAO Mei-rong;LAI Zhong-hong;XIAO Feng(Male Ward,Department of Early Intervention,the Third People's Hospital of Ganzhou City,Jiangxi Province,Ganzhou 341000,China;Outpatient Clinic,the Third People's Hospital of Ganzhou City,Jiangxi Province,Ganzhou 341000,China)

机构地区：[1]江西省赣州市第三人民医院早期干预科男病区,江西赣州341000 [2]江西省赣州市第三人民医院门诊部,江西赣州341000

出　　处：《中国当代医药》2020年第35期82-85,共4页China Modern Medicine

基　　金：江西省赣州市指导性科技计划项目(GZ2019ZSF207)。

摘　　要：目的探讨阿立哌唑联合米氮平治疗躯体形式障碍的效果。方法选取2019年6月~2020年3月赣州市第三人民医院收治的100例躯体形式障碍患者作为研究对象,根据抽签法将其分为对照组与观察组,每组各50例。对照组采用米氮平治疗,观察组采用阿立哌唑联合米氮平治疗。比较两组治疗前后的病情严重状态、心理状态和临床副反应发生情况。结果两组治疗前的病情严重程度、心理状态比较,差异无统计学意义(P>0.05)。观察组患者治疗后8周的症状自评量表(SCL-90)评分为(74.32±8.24)分,低于对照组的(100.24±10.15)分,差异有统计学意义(P<0.05)。观察组患者治疗后8周的汉密尔顿焦虑量表(HAMA)评分为(13.52±1.26)分,低于对照组的(20.12±1.45)分,汉密尔顿抑郁量表(HAMD)评分为(14.08±1.32)分,低于对照组的(21.27±1.60)分,差异有统计学意义(P<0.05)。观察组患者治疗后2、8周的临床副反应量表(TESS)评分[(30.12±1.24)、(12.32±1.27)分]低于对照组[(48.27±2.15)、(25.48±2.65)分],差异有统计学意义(P<0.05)。结论采用阿立哌唑联合米氮平方案对躯体形式障碍患者进行治疗,可降低患者的疾病严重程度,缓解负面情绪,减少用药后不良作用,推广应用价值高。Objective To investigate the effect of Aripiprazole combined with Mirtazapine in the treatment of somatoform disorders.Methods A total of 100 patients with somatoform disorders admitted to the Third People's Hospital of Ganzhou City from June 2019 to March 2020 were selected as the research subjects.By drawing lots method,they were divided into a control group and an observation group,with 50 cases in each group.In the control group,Mirtazapine was used,and in the observation group,Aripiprazole combined with Mirtazapine was added.The disease condition,psychological state,and clinical side effect before and after treatment in the two groups were compared.Results There were no statistically significant differences between the two groups in the severity of disease and psychological state before treatment(P>0.05).The self-rating symptom scale(SCL-90)score of the observation group eight weeks after treatment was(74.32±8.24)points,lower than that of the control group of(100.24±10.15)points,and the difference was statistically significant(P<0.05).The Hamilton anxiety scale(HAMA)score eight weeks after treatment was(13.52±1.26)points in the observation group,lower than that in the control group of(20.12±1.45)points,and the Hamilton depression scale(HAMD)score was(14.08±1.32)points,lower than that in the control group of(21.27±1.60)points,the differences were statistically significant(P<0.05).Thereatment emergent symptom scale(TESS)scores of patients in the observation group at 2,8 weeks after treatment([30.12±1.24],[12.32±1.27]points)were lower than those of the control group([48.27±2.15],[25.48±2.65]points),the differences were statistically significant(P<0.05).Conclusion The combination of Aripiprazole and Mirtazapine for patients with somatoform disorders can reduce the severity of the disease,alleviate negative emotions,reduce the adverse effect after medication,and has high promotion and application value.

关 键 词：阿立哌唑 米氮平 躯体形式障碍 症状严重程度 副作用 

分 类 号：R395.1[哲学宗教—心理学]